U.S. markets close in 3 hours 20 minutes
  • S&P 500

    4,452.36
    +3.38 (+0.08%)
     
  • Dow 30

    34,782.85
    +18.03 (+0.05%)
     
  • Nasdaq

    15,028.36
    -23.88 (-0.16%)
     
  • Russell 2000

    2,259.12
    +0.08 (+0.00%)
     
  • Crude Oil

    73.96
    +0.66 (+0.90%)
     
  • Gold

    1,752.60
    +2.80 (+0.16%)
     
  • Silver

    22.44
    -0.23 (-1.03%)
     
  • EUR/USD

    1.1722
    -0.0025 (-0.21%)
     
  • 10-Yr Bond

    1.4460
    +0.0360 (+2.55%)
     
  • GBP/USD

    1.3686
    -0.0035 (-0.25%)
     
  • USD/JPY

    110.7230
    +0.4220 (+0.38%)
     
  • BTC-USD

    42,278.93
    -1,577.46 (-3.60%)
     
  • CMC Crypto 200

    1,051.35
    -51.71 (-4.69%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The death of a patient in a solid tumor trial hit Poseida Therapeutics Inc (NASDAQ: PSTX) hard last August, but since then, the hold has been lifted, and it is now reporting some early data from that same therapy.

  • The Company announced interim results for P-PSMA-101, solid tumor autologous CAR-T product candidate for metastatic castrate-resistant prostate cancer (mCRPC).

  • The Company was bullish on the presentation today, but investors apparently were not impressed. The caveat is that it is Phase 1 trial with only heavily pretreated nine patients.

  • Investigators tracked a significant, 50%-plus drop in Prostate-Specific Antigen (PSA) levels in 3 of those patients.

  • One patient had a complete response at the lowest dose. Perhaps just as much as efficacy, safety will be keenly watched.

  • Three cases of low-grade possible Cytokine Release Syndrome were observed, managed well with early treatment.

  • No cases of neurotoxicity were observed as of the cutoff date.

  • Related Content: Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma.

  • Price Action: PSTX shares are down 17.1% at $8.88 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.